[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C][N][=C][N][Branch2][Ring2][Ring1][C][=Branch1][C][=O][/C][=Branch2][Ring1][#Branch1][=C][/C][=C][C][=Branch1][S][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C@@H1][Branch1][Ring1][C][O][O][Cl][/S][Ring2][Ring1][Ring2][C][=C][C][=C][C][=C][Ring1][=Branch1][C]"}, {"from": "gpt", "value": "The molecule is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.  Ponesimod was granted FDA approval on 18 March 2021."}]